Skip to main content
. 2021 May 14;10(5):581. doi: 10.3390/antibiotics10050581

Figure 5.

Figure 5

Figure 5

Effectivity of PLGA RG-503H nanoparticles on infected human endothelial cells in vitro. (A) MTT assay was performed to assess toxicity of PLGA RG-503H nanoparticles on human aortic endothelial cells. No significant difference was observed between untreated and treated cells after exposure for 24 h. (B) S. aureus 8325-4-infected endothelial cells were treated with either concentrated vancomycin solution (0.5 mg/mL), or both vancomycin solution and 10% vancomycin-loaded nanoparticles (0.5 µg/mL). Cells were lysed, and the total amount of external and internal S. aureus was quantified then expressed as colony forming units. The control group not exposed to any antibiotics displayed significant bacterial growth. Cells only treated with vancomycin solution were capable of reducing total S. aureus growth (p = 0.0003). Notably, cells treated with both concentrated and encapsulated vancomycin were capable of significantly reducing total S. aureus levels even more so than cells only treated with vancomycin solution (p = 0.045). Results are the mean values ± SEM of three independent experiments using 1-way ANOVA assuming unequal variances followed by Tukey’s post hoc tests. p < 0.05 indicates statistical significance. * p < 0.05, *** p < 0.001.